Metropolis Q2FY26 Growth Highlights

  Published 9 months ago

Metropolis Healthcare posted strong Q2FY26 growth across diagnostics, wellness, B2C, and B2B segments with profitability.

  • Core Diagnostics, Scientific Pathology, Agra, DAPIC, and TruHealth drove 25‑36% YoY segment growth across segments.
  • B2C revenues rose 16% YoY; B2B surged 34% thanks to core diagnostics expansion in 2025.
  • Acquired Ambika Pathology, adding Kolhapur presence; the company remains debt‑free with Rs 55 crore cash and growth.

You might like these

Dalmia Bharat Q1 Profit Surges 167%

Bajaj Auto August 2025 Sales

Kirloskar Pneumatic Q1 Profit Up 4%

Biocon Expands Tablet Production with $30M OSD Plant

Mphasis Launches AI CoE in Argentina

India GST Revamp: New Rates, Luxury Tax

GSCL Expands US Reach via PDS Acquisition

News that matters the most ⚡